Bio

Dr. Franc has over 15 years of experience in clinical nuclear medicine with particular expertise in PET-CT. He publishes and lectures predominantly on applications and innovations of PET-CT. As a clinical leader, Dr. Franc has developed programs for the early adoption and implementation of nuclear-based imaging and therapeutic technologies including combined positron emission tomography (PET) and computed tomography (CT) (combined PET-CT) and combined single photon emission computed tomography and CT (SPECT-CT) for quantitative oncologic and cardiac applications. Dr. Franc has experience in all aspects of PET radiopharmaceutical development, spanning the design of molecules, synthesis of radioligands, and use in animal and human imaging. He also has expertise in quantitative image analysis, development of novel post-processing image reconstruction methods, and the application of artificial intelligence in human diagnostics. Along with radiochemistry and radiopharmacy colleagues at the UCSF Cyclotron Facility, Dr. Franc has implemented new radiopharmaceuticals in pre-clinical and clinical research PET imaging as well as for clinical PET with applications in cancer, infectious disease (HIV), and autoimmune disease (RA).

In addition to translational science and clinical research, Dr. Franc has established himself in the area of health policy. His research, publications, and lectures in health policy focus on improving value of healthcare through decrease in variability and implementation of precision health techniques into the clinic.

CLINICAL FOCUS
• Nuclear Medicine

ACADEMIC APPOINTMENTS
• Clinical Professor, Radiology - Rad/Nuclear Medicine

PROFESSIONAL EDUCATION
• Medical Education: University of Southern California Keck School of Medicine Registrar (2000) CA
• Board Certification: Nuclear Medicine, American Board of Nuclear Medicine (2003)
• Residency: Stanford University Nuclear Medicine Residency (2003) CA
• Internship: Stanford University General Surgery Residency (2001) CA
Publications

PUBLICATIONS

- Identifying tests related to breast cancer care in claims data. *The Breast Journal*
  Franc, B. L., Thombley, R., Luo, Y., Boscardin, W. J., Rugo, H. S., Seidenwurm, D., Dudley, R. A.
  2019

- Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management. *Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine*
  2019

- Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer
  Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019

- Prospective evaluation of F-18-DCFPyL Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels
  Harrison, C., Song, H., Franc, B. L., Guja, K., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019

- Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer
  SOC NUCLEAR MEDICINE INC.2019

- Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans. *Journal of Digital Imaging*
  Nobashi, T., Zacharias, C., Ellis, J. K., Ferri, V., Koran, M. E., Franc, B. L., Iagaru, A., Davidzon, G. A.
  2019

- Translational Radiomics: Defining the Strategy Pipeline and Considerations for Application-Part 2: From Clinical Implementation to Enterprise *Journal of the American College of Radiology*
  Shaikh, F., Franc, B., Allen, E., Sala, E., Awon, O., Hendrata, K., Halabi, S., Mohiuddin, S., Malik, S., Hadley, D., Shrestha, R.
  2018; 15 (3): 543–49

- Translational Radiomics: Defining the Strategy Pipeline and Considerations for Application-Part 1: From Methodology to Clinical Implementation *Journal of the American College of Radiology*
  Shaikh, F., Franc, B., Allen, E., Sala, E., Awon, O., Hendrata, K., Halabi, S., Mohiuddin, S., Malik, S., Hadley, D., Shrestha, R.
  2018; 15 (3): 538–42

  2017; 77 (11): 2893-2902

- Development of an optimized activatable MMP-14 targeted SPECT imaging probe *Bioorganic & Medicinal Chemistry*
  2009; 17 (2): 653-659

- Correcting tumour SUV for enhanced bone marrow uptake: retrospective F-18-FDG PET/CT studies *Nuclear Medicine Communications*
  Teo, B., Badiee, S., Hadi, M., Lam, T., Johnson, L., Seo, Y., Bacharach, S. L., Hasegawa, B. H., Franc, B. L.
  2008; 29 (4): 359-366

- Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation *Bioconjugate Chemistry*
  2006; 17 (3): 787-796
• The role of a positron- and high-energy gamma photon probe in intraoperative localization of recurrent melanoma *CLINICAL NUCLEAR MEDICINE*
  Franc, B. L., Mari, C., Johnson, D., Leong, S. P.
  2005; 30 (12): 787-791

• Pericardial lymph node involvement in lymphoma as identified on PET *CLINICAL NUCLEAR MEDICINE*
  Franc, B., Yoshida, E., Herfkens, R., Goris, M.
  2004; 29 (11): 741-742

• Apoptosis in a rodent model of cranial suture fusion: In situ imaging and gene expression analysis *PLASTIC AND RECONSTRUCTIVE SURGERY*
  2004; 113 (7): 2037-2047

• Oral administration of F-18FDG to evaluate a single pulmonary nodule by positron emission tomography in a patient with poor intravenous access *CLINICAL NUCLEAR MEDICINE*
  Franc, B., Carlisle, M. R., Segall, G.
  2003; 28 (7): 541-544

• Low uptake of Tc-99m tetrofosmin in lung cancer - A case report *CLINICAL NUCLEAR MEDICINE*
  Franc, B., Goris, M.
  2002; 27 (10): 698-700